story of the week
Avalglucosidase Alfa vs Alglucosidase Alfa in Late-Onset Pompe Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Lancet Neurol 2021 Dec 01;20(12)1012-1026, J Diaz-Manera, PS Kishnani, H Kushlaf, S Ladha, T Mozaffar, V Straub, A Toscano, AT van der Ploeg, KI Berger, PR Clemens, YH Chien, JW Day, S Illarioshkin, M Roberts, S Attarian, JL Borges, F Bouhour, YC Choi, S Erdem-Ozdamar, O Goker-Alpan, A Kostera-Pruszczyk, KA Haack, C Hug, O Huynh-Ba, J Johnson, N Thibault, T Zhou, MM Dimachkie, B SchoserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.